Lipomembranous Panniculitis Induced by Repeated Progesterone Injections for Libido Enhancement: A Case Report
DOI:
https://doi.org/10.20344/amp.23042Keywords:
Injections, Intramuscular, Injections, Subcutaneous, Libido/drug effects, Panniculitis/chemically induced, Progesterone/adverse effectsAbstract
The use of subcutaneous and intramuscular progesterone injections for non-therapeutic purposes has become increasingly common in Africa, particularly in Angola, where weak regulation allows unsupervised use. We report the case of a 26-year-old Angolan woman who developed lipomembranous panniculitis after six months of daily subcutaneous progesterone injections for libido enhancement at a non-medical center. She presented with erythematous-brown nodules and plaques, and a skin biopsy confirmed granulomatous inflammation and adipocyte death. Treatment with prednisolone and naproxen resolved the inflammation, but hyperpigmentation persisted. This case highlights the serious risks of off-label progesterone injections, particularly in unregulated aesthetic procedures, and underscores the need for stricter regulations and public health interventions.
Downloads
References
Quiala S. Jardas: os efeitos nefastos da busca pelo corpo perfeito. 2023. [cited 2025 Sep 11]. Available from: https://www.dw.com/pt-002/jardas-em-angola-os-efeitos-nefastos-da-busca-pelo-corpo-perfeito/video-65379096.
Hibshi A, Aldriweesh A, Saeed B, Coskun S, Awartani K. Subcutaneous progesterone (Prolutex)® for luteal phase support in cycles of in vitro fertilization-embryo transfer- a retrospective cohort study. Clin Obstet Gyneol Reprod Med. 2020;6:1-5.
Westhoff C. Depot-medroxyprogesterone acetate injection (Depo-Provera®): a highly effective contraceptive option with proven long-term safety. Contraception. 2003;68:75-87.
Jacobstein R, Polis CB. Progestin-only contraception: injectables and implants. Best Pract Res Clin Obstet Gynaecol. 2014;28:795-806.
Baker VL, Jones CA, Doody K, Foulk R, Yee B, Adamson GD, et al. A randomized, controlled trial comparing the efficacy and safety of aqueous subcutaneous progesterone with vaginal progesterone for luteal phase support of in vitro fertilization. Hum Reprod. 2014;29:2212-20.
Patterson JW. Weedon’s skin pathology. 5th ed. London: Elsevier; 2021.
Xiao W, Huang X, Lin C, Liu Y, Chen S, Wu R. Panniculitis caused by progesterone injection can be treated by physical therapy. Dermatol Ther. 2021;34:e14501.
Jödicke AM, Dahmke H, Damke B, Schäublin M, Kullak-Ublick GA, Weiler S. Severe injection site reactions after subcutaneous administration of Sayana©. Swiss Med Wkly. 2017;147:w14432.
Requena L, Yus ES. Panniculitis. Part II. Mostly lobular panniculitis. J Am Acad Dermatol. 2002;45:325-64.
Casado-Espada NM, de Alarcón R, de la Iglesia-Larrad JI, Bote-Bonaechea B, Montejo ÁL. Hormonal contraceptives, female sexual dysfunction, and managing strategies: a review. J Clin Med. 2019;8:908.
Gouveia C, Soares Almeida LM. Paniculitis lipomembranosa: correlación clínico-patológica de 8 casos. Actas Dermosifiliogr. 2006;97:379-84.
Sanmartín O, Requena C, Requena L. Factitial panniculitis. Dermatol Clin. 2008;26:519-27.
Roda Â, Marcos-Pinto A, Filipe P, Soares-de-Almeida L, Maia-Silva J. Lipomembranous panniculitis after subcutaneous medroxyprogesterone acetate injections used for buttocks augmentation in Africa. Int J Dermatol. 2022;61:e83-5.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Acta Médica Portuguesa
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All the articles published in the AMP are open access and comply with the requirements of funding agencies or academic institutions. The AMP is governed by the terms of the Creative Commons ‘Attribution – Non-Commercial Use - (CC-BY-NC)’ license, regarding the use by third parties.
It is the author’s responsibility to obtain approval for the reproduction of figures, tables, etc. from other publications.
Upon acceptance of an article for publication, the authors will be asked to complete the ICMJE “Copyright Liability and Copyright Sharing Statement “(http://www.actamedicaportuguesa.com/info/AMP-NormasPublicacao.pdf) and the “Declaration of Potential Conflicts of Interest” (http:// www.icmje.org/conflicts-of-interest). An e-mail will be sent to the corresponding author to acknowledge receipt of the manuscript.
After publication, the authors are authorised to make their articles available in repositories of their institutions of origin, as long as they always mention where they were published and according to the Creative Commons license.
